Brokerages expect that LeMaitre Vascular Inc (NASDAQ:LMAT) will announce earnings of $0.21 per share for the current quarter, Zacks reports. Three analysts have made estimates for LeMaitre Vascular’s earnings. LeMaitre Vascular reported earnings of $0.43 per share in the same quarter last year, which would indicate a negative year-over-year growth rate of 51.2%. The business is expected to report its next quarterly earnings results on Thursday, July 25th.
On average, analysts expect that LeMaitre Vascular will report full year earnings of $0.83 per share for the current year, with EPS estimates ranging from $0.82 to $0.84. For the next year, analysts forecast that the business will post earnings of $0.92 per share, with EPS estimates ranging from $0.89 to $0.95. Zacks’ EPS averages are an average based on a survey of research analysts that cover LeMaitre Vascular.
LeMaitre Vascular (NASDAQ:LMAT) last posted its quarterly earnings data on Wednesday, May 1st. The medical instruments supplier reported $0.17 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.19 by ($0.02). The business had revenue of $28.48 million for the quarter, compared to the consensus estimate of $27.94 million. LeMaitre Vascular had a net margin of 20.92% and a return on equity of 16.76%. LeMaitre Vascular’s quarterly revenue was up 9.6% on a year-over-year basis. During the same period in the prior year, the business posted $0.19 EPS.
Several equities research analysts recently issued reports on the company. Barrington Research reissued a “buy” rating and set a $32.00 price objective on shares of LeMaitre Vascular in a research note on Thursday, May 2nd. ValuEngine lowered LeMaitre Vascular from a “hold” rating to a “sell” rating in a research note on Thursday, April 18th. BidaskClub lowered LeMaitre Vascular from a “hold” rating to a “sell” rating in a research note on Tuesday, April 16th. Finally, Zacks Investment Research lowered LeMaitre Vascular from a “buy” rating to a “hold” rating in a research note on Tuesday, May 7th. Six equities research analysts have rated the stock with a hold rating and one has issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $31.00.
A number of hedge funds have recently modified their holdings of LMAT. Bank of Montreal Can lifted its stake in LeMaitre Vascular by 99.1% during the fourth quarter. Bank of Montreal Can now owns 1,113 shares of the medical instruments supplier’s stock worth $26,000 after purchasing an additional 554 shares during the last quarter. BNP Paribas Arbitrage SA lifted its stake in LeMaitre Vascular by 66,640.0% during the first quarter. BNP Paribas Arbitrage SA now owns 3,337 shares of the medical instruments supplier’s stock worth $103,000 after purchasing an additional 3,332 shares during the last quarter. Municipal Employees Retirement System of Michigan bought a new stake in LeMaitre Vascular during the fourth quarter worth about $106,000. Metropolitan Life Insurance Co. NY lifted its stake in LeMaitre Vascular by 373.8% during the fourth quarter. Metropolitan Life Insurance Co. NY now owns 5,629 shares of the medical instruments supplier’s stock worth $133,000 after purchasing an additional 4,441 shares during the last quarter. Finally, Oregon Public Employees Retirement Fund bought a new stake in LeMaitre Vascular during the fourth quarter worth about $143,000. 77.10% of the stock is owned by hedge funds and other institutional investors.
NASDAQ:LMAT traded up $0.13 during trading hours on Monday, hitting $27.98. 232,866 shares of the company’s stock traded hands, compared to its average volume of 84,184. The company has a market cap of $547.84 million, a price-to-earnings ratio of 33.31, a P/E/G ratio of 2.80 and a beta of 1.17. LeMaitre Vascular has a 52 week low of $21.79 and a 52 week high of $38.99. The company has a fifty day moving average of $26.91.
The company also recently declared a quarterly dividend, which was paid on Thursday, June 6th. Shareholders of record on Wednesday, May 22nd were paid a dividend of $0.085 per share. This represents a $0.34 annualized dividend and a yield of 1.22%. The ex-dividend date was Tuesday, May 21st. LeMaitre Vascular’s dividend payout ratio (DPR) is currently 40.48%.
About LeMaitre Vascular
LeMaitre Vascular, Inc designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. The company offers angioscope, a fiber optic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries or veins; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to temporarily perfuse the blood and other fluids into the vasculature.
Read More: What does an outperform rating mean?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for LeMaitre Vascular Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular and related companies with MarketBeat.com's FREE daily email newsletter.